JUL 3 0 2002

Atty. Docket No.:

8039/1090

**PATENT** 

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Riechmann, et al.

Serial No.:

09/710,444

Filed: Entitled:

November 10, 2000

"Selection System"

Examiner:

B. Celsa

Group Art Unit: 16

: 1627

Conf. No.: 2736

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to: U.S. Patent & Trademark Office, Box: Sequence, P.O. Box 2327, Arlington, VA 22202.

Mary Wilson

Name of Parson Mailing Paper

Signature of Person Mailing Paper

U.S. Patent and Trademark Office

Box: Sequence P.O. Box 2327

Arlington, VA 22202

**AMENDMENT** 

Sir:

This is filed in response to the Examiner's Notice to Comply with nucleotide or amino acid sequence listing requirements mailed February 27, 2002 in the above noted U.S. Patent Application. Kindly enter the following amendments and remarks.

In the Specification:

Replace the paragraph at lines 14 to 23 on page 15 with the following replacement paragraph:

A sequence (PAGLSEGSTIEGRGAHE; SEQ ID NO: 1) comprising several proteolytic sites is inserted in the flexible glycine-rich region between the D2 and D3 domains of the phage p3. Incubation of the phage (fd-K108) under native conditions with trypsin, thermolysin or subtilisin now resulted in almost complete loss of infectivity (from  $10^7$  to < 10 TU/ml) and incubation with Glu-C and chymotrypsin resulted in a major loss (from  $10^7$  to  $10^4$  TU/ml). This indicates that these proteases cleave the new linker. However incubation with Factor Xa, Arg-C or thrombin did not lead to a loss in infectivity, despite the presence of potential cleavage sites

01